



Abstracts from the HTAi 2017 Annual Meeting
in Rome, Italy, June 17-21

International Journal of

Technology Assessment in Health Care

Conference Theme: Towards an HTA Ecosystem:
From Local Needs to Global Opportunities



ISSN: 0266-4623

CAMBRIDGE
UNIVERSITY PRESS

International Journal of Technology Assessment in Health Care

Official Journal of Health Technology Assessment International

Editor-in-Chief

Wendy Babidge, BApp Sci (Hons), Ph.D., Grad Dip Bus, GAICD

Director of Research, Audit and Academic Surgery Division, Royal Australasian College of Surgeons

Adjunct Associate Professor, University of Adelaide

199 Ward St, North Adelaide South Australia 5006, Australia

Email: wendy.babidge@adam.com.au

Aims and Scope: The *International Journal of Technology Assessment in Health Care* has as its specific scope of interest the generation, evaluation, diffusion, and use of health care technology. It addresses the diverse audience of health care providers within medicine, public health, nursing, and the allied health professions; decision makers in government, industry, and health care organizations; and the scholarly disciplines such as ethics, economics, law, history, sociology, psychology, and engineering. The journal aims to fill the needs of those interested in the complexities of interaction between people and technology; technology as a force in social and organizational change; and technology as it is created, produced, applied, and paid for. It examines descriptively and analytically the effects of technology as perceived from the vantage point of different academic disciplines and policy-making organizations and examines methods necessary to conduct studies and evaluations of technology.

The focus of the journal is the international health care community. The experience of different countries in their encounter with health care technology, viewed comparatively, is invaluable to understanding its effects. Further, it is important to establish ties with the scholars, governments, and private institutions concerned with health care technology so that the experiences and learning of the international community in its parts can benefit the whole. The use of technology in health care has created some of the major dilemmas in society today. The journal serves as a forum for the wide range of professionals interested in the assessment of medical technology, its consequences for patients, and its impact on society.

Publishing, Advertising, and Subscription Offices: Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. (for U.S.A., Canada, and Mexico); or Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK (for U.K. and elsewhere).

2017 Subscription Information: *International Journal of Technology Assessment in Health Care* (ISSN 0266-4623) is

published bimonthly in February, April, June, August, October, and December by Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006; Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK. Annual institutional subscription rates for Volume 33 (2017): Institutions online only US \$679.00, and online only UK and elsewhere £390.00. Individuals online only US \$326.00, and online only UK and elsewhere £183.00. Single part: US \$130.00 in the U.S.A., Canada and Mexico; UK £75.00 and elsewhere. Online only for all institutions. Print editions ceased in 2014. Back volume prices are available upon request. *International Journal of Technology Assessment in Health Care* and other Cambridge journals can be found at <http://journals.cambridge.org>

© Cambridge University Press 2018

All rights reserved. No part of this publication may be reproduced, in any form or by any means, electronic or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions.permission.htm>

Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center, <http://www.copyright.com>, email: info@copyright.com.

Postmaster: Send address changes in the U.S.A. and Canada to: *International Journal of Technology Assessment in Health Care*, Journals Department, Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. Send address changes elsewhere to: *International Journal of Technology Assessment in Health Care*, Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK.

Founding Editors: Egon Jonsson and Stanley J. Reiser

Contents

Oral Presentations	1
OP01 Cross Border Cooperation On High-Cost-Capital Investments In Health	1
OP02 A Managed Access Approach To Appraising New Cancer Drugs In England	1
OP03 Trends In The National Institute For Health And Care Excellence (NICE) Cancer Drugs Fund Reconsiderations	2
OP04 Lessons Learnt When Implementing A Health Technology Assessment Institution In Costa Rica	3
OP06 Past Speculations Of Future Health Technologies: What Did They Predict?	4
OP07 Towards Better Outcomes: New Standard For Placing A Value On Health	5
OP08 National Institute for Health Research Health Technology Assessment Programme Research Funding And United Kingdom Burden Of Disease	5
OP11 Structural Uncertainty In Economic Modelling For Smoking Cessation	6
OP15 The Incremental Cost Of Delirium Following Aortic Valve Replacement	7
OP16 A Patient-centered Value Framework For Healthcare In Hemophilia	8
OP19 Unlocking The Potential Of Established Products: Need For Incentives	9
OP21 Involving Clinical Experts In Prioritizing Topics For Health Technology Assessment: A Randomized Controlled Trial	9
OP22 Societal Perspective On Cost Drivers For Health Technology Assessment	10
OP24 A Framework For Improved Systems Of Care In Myocardial Infarction	11
OP25 Evidence Gathering Across Key Stakeholders Involved In Early Health Technology Assessment	12
OP27 Patient-Reported Outcome Measures In Carotid Artery Revascularization	12
OP28 Health Apps: A Proposed Framework To Guide Clinical Risk Assessment	13
OP30 Health Technology Assessment And The Decision-Making Process Of New Drug Listing In Hong Kong	14
OP33 Developing A Public Version Of A Health Technology Assessment Report	15
OP35 Involving Members Of The Public In A National Screening Programme Health Technology Assessment	16
OP37 Can Local Ultra-Orphan Patient Evidence Shape Global Understanding?	16
OP38 Improving The Patient Centricity Of Value Assessments: A Rubric	17
OP40 First Case Of Disinvestment Using Real-World Evidence In Brazil	18
OP42 Cost-Benefit Of Computed Tomography In Secondary Hospitals In China	19
OP43 Unconventional Health Technology Assessment Use: Diagnosis Of Likely Emerging Tropical Diseases	19
OP44 Cost-Effectiveness Of Hepatitis C Virus Screening In Swiss Prisons Using Rapid Tests	20
OP45 Study On Effects Of Community-acquired Pneumonia Clinical Pathway On Antibiotics' Utilization	21
OP46 Addressing National Health Service (NHS) Priorities: Medtech Innovation Briefings	22
OP49 Restrictive Versus Non-Restrictive Drug Reimbursement Systems	22
OP50 European Assessments Of Medical Devices: Avenues For Improvement	23
OP51 Thrombectomy In France: A National Use Of European Network for Health Technology Assessment (EUnetHTA) Joint Assessment	24
OP55 Health Technology Assessment In Children And Adolescents: Adolescent Preferences For Child Health Utility 9D Health States	24
OP58 Testing Of A Multiple Criteria Decision Analysis Value Framework With Decision Makers Across Europe	25
OP60 Ramucicromab In Gastric Cancer Treatment: An Economic Evaluation	26
OP61 Cost-Utility Analyses Of Biologics For Refractory Ulcerative Colitis	27
OP64 Economic Impact Of Cardiac Device Remote Monitoring In South Korea	28

OP67 Cost-Effectiveness of Human Papillomavirus-based Primary Cervical Screening In Ireland	28
OP68 An Evidence-Based Clinical Pathways Program Reduces Low-Value Care	29
OP69 Hospital-based Health Technology Assessment Is Applicable To Investment Decision-Making Process	30
OP70 Economic Impact Of Macular Edema Diseases, A Retrospective Study	31
OP71 Evidence-Based Searching For Health Technology Assessment – Keeping Up-to-Date With Summarized Research In Information Retrieval (SuRe Info)	31
OP72 Adherence Of Budget Impact Analyses To Principles Of Good Practice	32
OP73 Using Visualization In Scoping The Literature For A Prognostic Health Technology Assessment	33
OP75 Implementing Risk Stratification In Primary Care: A Qualitative Study	34
OP76 Economic Contributions Of Older Adults In Europe	35
OP77 Identifying Topics For Health Technology Assessment: The German “ThemenCheck Medizin”	35
OP78 Patient Involvement In European Health Technology Assessment Focus Group With Cardiac Patients	36
OP79 Experimenting HTAi Patient Group Submission Template To Involve Patients	37
OP83 Value Assessment Framework: Evidence-Informed Deliberative Processes	38
OP85 Value To Society Of A Nationwide Patient Blood Management Program	38
OP86 Identifying Surgical Procedures Of Low Or No-Added Value In Spain	39
OP89 Using Economic Evidence To Set Priorities In Ghana: The Case Of Malaria	40
OP91 Health Technology Assessment On The Da Vinci Surgical System Using Real World Data In China	41
OP92 Addressing Challenges Of Implementing A Health Technology Assessment Framework In South Africa	41
OP93 Conditional Financing In Health Technology Assessment Practice: The Dutch Experience	42
OP94 Is The National Institute for Health And Care Excellence In The United Kingdom More Innovation-Friendly Than The German Institute For Quality And Efficiency in Health Care In Germany?	43
OP95 An Update On The Economic Value Of A Statistical Life Year In Europe	44
OP97 Program Budgeting Marginal Analysis For The Real World	44
OP100 How Health Technology Assessment Is Adapting To Orphan Drugs In Canada – Not!	45
OP101 Do We Need To Extend Health Technology Assessment To Health Enhancement Assessment?	46
OP103 CONITEC’s Rapid Reports As Technical Support In The Litigation	46
OP104 Health Technology Assessment’s Ethical Evaluation: Understanding The Diversity Of Approaches	47
OP105 Systematically Reconstructing Trial Context-Role For CLUSTER Searches?	48
OP106 The Impact Of Searching Fewer Databases In Health Technology Assessment Rapid Reviews	49
OP107 Sources Used To Find Studies For Systematic Reviews Of Economic Evaluations	50
OP108 Health Intervention Assessment Report Adaptation: Tunisian Experience	50
OP110 Survey Of Health Technology Assessment Evaluation Strategies For Patient And Public Involvement	51
OP115 Effect Of Multiple Drug Resistance On Costs For Patients With Intra-Abdominal Infections in China	52
OP116 Cost-Effectiveness Of Sacubitril/Valsartan In Heart Failure	52
OP118 Cost-Effectiveness Analysis Of Molecular Profile Selection For Advanced Head And Neck Cancer	53
OP119 Advanced Therapy Medicinal Products: Are Current Health Technology Assessment Methods Suitable?	54
OP120 Recommendations From The Newly Developed French National Authority For Health (HAS) Guide On Budget Impact	55
.....	

OP123 Health Technology Assessment In Digital Health: A Rapid Approach To Assess Health Apps.....	56
OP124 Can Registry Failures Be Compensated By Medico-Administrative Database.....	56
OP125 A New Collaborative Approach To Assess Innovative Health Technologies.....	57
OP126 The European Network For Health Technology Assessment (EUneHTA) Template To Aid Health Technology Assessment-based Decisions.....	58
OP127 Analysis Of The Competencies To Be Acquired In Health Technology Assessment.....	59
OP129 Predictors Of Effectiveness In Patients With Rheumatoid Arthritis.....	59
OP131 Cost-Effectiveness Of Dexamethasone And Adalimumab For Uveitis.....	60
OP132 How A Shared Management Of Home Infusion Can Control Expenditure.....	61
OP133 Health Technology Assessment In Brazil: A 5-year Review Of Brazilian Health System (CONITEC) Activities.....	62
OP134 Predictors Of Public Health Outcomes: A Case Study From Turkey.....	62
OP135 Confirmatory Versus Explorative Endpoints In Drug Approval Versus Health Technology Assessment.....	63
OP136 Clinical Benefit Of Oncological Therapies At The Time Of Approval.....	64
OP138 Access To Orphan Drugs In The United Kingdom And Other European Countries.....	64
OP141 Patient Relevant Outcome Measures As Predictors Of Healthcare Use In Multiple Sclerosis.....	65

Poster Presentations..... **67**

PP001 Ultrasound To Guide Treatment Decisions In Rheumatoid Arthritis.....	67
PP002 Sudden Cardiac Arrest: Wearable Cardioverter-Defibrillator Therapy.....	68
PP006 Ebola In The Netherlands: Costs Of Preparedness And Response.....	68
PP007 Technology Adoption In Hospitals - Balancing Incentives - A Survey.....	69
PP008 Health Technology Assessment Analysis Of New Biological Drugs In Chronic Inflammatory Diseases.....	70
PP009 Quality Assessment In A Clinical Setting: A Look Upstream From Health Technology Assessment.....	71
PP011 Covering New Medical Devices With Low Cost-Effectiveness Evidence.....	71
PP012 Efficacy And Safety Of The ELIPSE Gastric Balloon For Weight Loss.....	72
PP013 Pain Management And Substance Abuse In Sickle Cell Disease Patients.....	73
PP014 Will A Proposed Policy In Japan, Health Gold License, Work?.....	74
PP015 Methodological Quality Of Health Technology Assessment Reports.....	74
PP017 Social Cost Benefit Analysis Of Cognitive Behavioral Therapy For Alcohol And Cannabis Addiction.....	75
PP018 Clinical Risk Prediction Scores For Venous Thromboembolism In Hospitalized Patients.....	76
PP019 Clostridium Difficile Infection Diagnosis: Hospital-based Health Technology Assessment.....	77
PP020 Decision-Making Beyond Evidence Alone – Topic Prioritization For Health Technology Assessment.....	77
PP021 Peer Review Innovations For Grant Applications: Efficient And Effective?.....	78
PP022 New Models Are Needed To Optimize The Management Of New Medicines.....	79
PP023 Applying Oncology Patient Registries As A Health Technology Assessment Tool.....	80
PP024 Changes In Reporting Characteristics Of Systematic Reviews For The United Kingdom.....	80
PP025 Thrombopoietin Receptor Agonist For Treatment Of Adults With Chronic Immune Thrombocytopenic Purpura.....	81
PP028 Hyperhidrosis Quality Of Life Measures: Review And Patient Perspective.....	82
PP029 Hospitalizations And Costs In Bipolar Disorder Patients Initiating Long-acting Injectable Antipsychotics.....	83
PP030 Socioeconomics Of Cardiac Rehabilitation: A Meta-Analysis.....	83

.....

PP031 iStent® For Open Angle Glaucoma: Standard Or Emerging Care ?	84
PP032 Holistic Patient Access Processes Of Medical Devices In South Korea	85
PP033 Patient And Public Involvement In Health Technology Assessment: The Brazilian Experience	86
PP037 Quality Criteria And Good Practices In The Health Technology Assessment Spanish Network	86
PP038 EQ-5D-3L Electronic Version Development For The Brazilian Population	87
PP039 Health Utility Values In Renal Cell Carcinoma: A Systematic Review	88
PP040 Hospitalization Costs In Schizophrenia: Long-acting Injectable Antipsychotics Versus Oral Antipsychotic Use	89
PP041 Universal Coverage Through Innovative Telediagnosis Technology	89
PP042 Rapid Health Technology Assessment - No Flare Reaction With Synolis V-A In Knee Osteoarthritis	90
PP044 Adherence To Enzyme Replacement Therapy In Gaucher Disease	91
PP046 Screening In Women Vaccinated Against Human Papillomavirus: Governing Innovation	92
PP047 Intravenous Iron Sucrose Therapy In Real-World Anemic Patients	92
PP048 Quality Of Health Care Through Integration: Experience Of Cochlear Implantation	93
PP049 Exploring The Utility Of A Validated Quality Appraisal Tool	94
PP050 Analysis Of Pharmacoeconomic Studies Published In The Scientific Electronic Library "eLIBRARY.RU" (RSCI)	95
PP052 Hospital-based Health Technology Assessment Of Prasugrel In Patients With Stent: Outpatient Use	96
PP053 A Case Study: Collective Individual Basis For The Judiciary Debate	96
PP054 The All Wales Patient Reported Outcome Measures (PROMs), Patient Reported Experience Measures (PREMs) and Effectiveness Program	97
PP059 National Survey Of Current United Kingdom Ambulance Service Transient Ischemic Attack Referral Pathways	98
PP060 Burden Of Nervous System Diseases On The Social Security System	99
PP061 Direct Cost Of Physiotherapeutic Devices Judicialization In Brazil	99
PP064 Registration Of Healthcare Mobile Apps In Brazil	100
PP066 Disseminate Results Through Social Video And Social Networks	101
PP068 Stakeholder Views On Peer Review Of National Institute for Health Research Grant Applications	102
PP069 Health Technology Assessment Of Radium-223 Dichloride In Resistant Metastatic Prostate Cancer	103
PP071 Health Technology Assessment In Bulgaria: A Review Of The First Fifteen Reports Assessed	103
PP072 Applying Sensitivity Analysis For Robust Choice Of Health Technologies	104
PP075 Has A Drug Replacement An Impact On Hospital Treatment? A Health Technology Assessment-debate	105
PP076 Research On Drug Policy Change In China Since 2009 New Medical Reform	106
PP077 Intravitreal Corticosteroids In Macular Edema: Quality Of The Evidence	107
PP079 The Construction Of Database Using Japanese National Claims Database	108
PP081 Relation Between Pain And Treatment/Activity Based On Mobile App Data	108
PP084 Diabetic Macular Edema: A Comparison Between Treatment Options	109
PP085 A Scoping Review Of Emergency Assessment And Referral Of Suspected Transient Ischemic Attack	110
PP086 Horizon Scanning In Multiple Sclerosis Decisions In Brazil	111
PP089 Health Technology Assessment Of An Automated Compounding Of Parenteral Nutrition	112
PP090 Reducing Low-Value Practices In Catalonia: Essencial Project	112
PP091 A Follow Up Study On Transcatheter Aortic Valve Implantation (TAVI)	113

PP092 Real World Data: Biologic Treatment For Naive Patients In Lazio Region	114
PP094 Autologous Stem Cell Transplantation For Multiple Sclerosis	115
PP095 Assessment Of Magmaris Resorbable Metal Stent In Patients With Angina	116
PP096 European Union-Health Technology Assessments For Medical Devices - How To Overcome Reimbursement Divergence	116
PP097 Challenges Of Rapid Reviews In Health Technology Assessment: Case Study From An Italian Region	117
PP100 Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections	118
PP101 A Procedural Method For Networking Local And Regional Stakeholders	119
PP102 Perceived Quality By Patients Hospitalized At Home Undergoing Domicillary Radiography	119
PP103 Characteristics Of Systems Applied To Language Rehabilitation	120
PP106 Regional Guidance On Aids For Ostomy	121
PP107 Amiodarone For Arrhythmia In Chagas Patients: A Systematic Review	121
PP108 Health Technology Assessment Educational Programs In The Russian Federation	122
PP109 Horizon Scanning For Information Providing In Brazil	123
PP110 Economic Impact Of Therapeutic Regime Reduction In The Hepatitis C Virus Infection	124
PP111 The Use Of Long-acting Injectable Antipsychotics In Schizophrenia	124
PP113 High-Sensitivity C-Reactive Protein (hsCRP) Measurements And Burden In Patients With History Of Myocardial Infarction	125
PP115 Patient And Public Involvement In Health Technology Assessment: Update Of A Systematic Review	126
PP116 Data Linkage Across Ambulance Services And Emergency Departments	126
PP117 Isosorbide And Nifedipine In Chagas Patients: A Systematic Review	127
PP120 Health Technology Assessment Framework To Capture The Full Value Of Value Added Medicines	128
PP122 Strengthening Ethics Compliance In A Large Research Program: Uganda	129
PP124 The HTAi Vortal: A Comparative Analysis	129
PP125 Evidence-based Policy Making – Bottom-Up Heuristic Engagement Process	130
PP126 MEA In Italy: Correlation Between Time To Payment By Result And Time To Off Treatment Curve	131
PP128 Regional Guidance On Spinal Cord Stimulation For Chronic Pain	132
PP129 Methodological Issues With Assessing Newborn Screening Tests	132
PP130 Nudging In Public Health: Accountability For Practical Wisdom	133
PP135 Stakeholder Involvement In A Health Technology Assessment Of Hyperhidrosis	134
PP137 Regional Process For Planning Medical Equipment Procurement In Italy	135
PP138 Italian Medicines Agency Registries Distribution By Managed Entry Agreements And By Anatomical Therapeutic Area	135
PP141 Legal Governance: How Does Law Circumscribe The Social Role Of Health Technology Assessment?	136
PP142 A Mental Health Hospital-based Health Technology Assessment In Quebec, Canada: Structure And Products	137
PP147 Physician And Patient Reported Anxiety And Depression In Hemophilia	138
PP148 Development And Evaluation Of A Tool Supporting Prescription Behavior	139
PP149 Assessment Of New Medical Devices With Administrative Databases	139
PP150 Rapid Analgesia For Prehospital Hip Disruption: A Feasibility Study	140
PP155 The Impact Of Lawsuits In The Brazilian Public Health System	141
PP156 New Information And Communication Technologies And Hospitals' Design	142
.....

PP166 From An Institutional Strategic Plan To A Knowledge Transfer Tool For Health Technology Assessment: Case Of Drug-eluting Stents	142
PP168 Combination Therapy Versus Intensification Of Statin Monotherapy	143
PP170 Health Impact Assessment Of Teleradiology Programs In Disadvantaged Areas	144
PP171 Immuno-Oncology: A Patient Perspective	145
PP172 Recruiting Academic Physicians Without Financial Conflict Of Interest	146

Vignette Presentations **147**

VP01 Effect Of Early Life Socioeconomic Status On Trajectories Of Chinese Elders Health	147
VP02 Are Journal Editors A Barrier To Publication Of Real World Evidence?	147
VP05 Comprehensive Evaluation Of An Evolving Transcatheter Technology	148
VP07 Collaboratively Modelling The Impact Of Interventions Retrospectively	149
VP08 Real-World Data Use In Health Technology Assessments: A Comparison Of Five Health Technology Assessment Agencies	149
VP09 Arthroplasty Registers As A Tool For Health Technology Assessment	150
VP13 Relation Between Magnetic Resonance Imaging Use And Hip Or Knee Replacements In The Organisation For Economic Co-operation And Development	151
VP14 Screening Recommendations For Socioeconomic Disadvantages In Pregnancy	152
VP15 A Comparison Of Reporting In United Kingdom Health Technology Assessment And Other Systematic Reviews	152
VP16 Interventional Management Of Hyperhidrosis: A Systematic Review	153
VP18 Early Awareness And Alert System In Sweden: History And Current Status	154
VP21 Telemedicine As A Tool For Public Health Planning	155
VP22 Cancer Drugs Fund Allocation Under The National Institute for Health and Care Excellence (NICE): The First Six Months	156
VP24 The Development Of A Quality Management Tool For Health Technology Assessment Agencies In Spain	156
VP25 African Countries Are Working Together To Enhance Medicine Use	157
VP26 Comparing Statistical Methods For Meta-Analysis Of Rare Event Data	158
VP28 The Use Of Ethnographic Fieldwork In Health Technology Assessment	159
VP29 Organizational Aspects In Health Technology Assessment: A New Approach For Future Assessments	160
VP30 Research And Analysis Of European Health Technology Assessment Processes	161
VP31 Health Technology Assessment Evidence On E-Health/M-Health Technologies: Fields For Improvement	161
VP32 Improving The Efficiency Of Early Awareness For Non-Drugs In Spain	162
VP33 Decision Making Clinical Scenarios: A Support Method For Health Technology Assessment	163
VP34 Economic Impact Of Influenza-Like-Illness In Vietnam	164
VP35 Economic Consequences Of A Restricted Dutch Sexually Transmitted Infection-Testing Policy	165
VP36 Cost-Effectiveness Of Non-Invasive Prenatal Testing For Down Syndrome	165
VP40 Comprehensive Evaluation Of Islet Transplantation For Type I Diabetes	166
VP44 Rapid Health Technology Assessment – High-Intensity Focused Ultrasound For Breast Fibroadenomas And Benign Thyroid Nodules	167
VP46 Cost Analysis Of Popliteal Aneurysm Management	168
VP47 Health Technology Assessment Of Intensive Care Ventilators For Pediatric Patients	168
VP48 The Costs And Cost-Effectiveness Of Bacillus Calmette-Guérin (BCG) Vaccination In Estonia	169
VP49 Brazilian Consumer Willingness To Pay For Dengue Vaccine (CYD-TDV)	170

VP51 Hospitalizations And Costs In Schizophrenia Patients Initiating Long-acting Injectable Antipsychotics.....	171
VP53 Cost-Utility Analysis: Adalimumab Versus Etanercept in Rheumatoid Arthritis – Brazil.....	171
VP54 Costs And Benefits Of Intensive Inpatient Rehabilitation After Stroke.....	172
VP55 Health Technology Assessment Of Orphan Drugs: The Case Of Hereditary Angioedema In Italy.....	173
VP57 Test-Retest Reliability Analysis Of The Patient Reported Outcomes Burdens And Experiences (PROBE) Study Questionnaire Test-Retest Reliability Analysis Of The PROBE Study Questionnaire.....	174
VP59 Patients Views On Providing Evidence; Feeding Into The Health Technology Assessment Ecosystem.....	175
VP60 The Importance Of Patient Organizations Involvement In Health Technology Assessment.....	176
VP61 Patients Views Of Health Technology Assessment At The National Institute Of Health And Care Excellence (NICE): Enhancing Involvement Opportunities.....	176
VP63 National Institute For Health And Care Excellence (NICE) Technology Appraisal Patient Expert Feedback: 15 month analysis.....	177
VP64 Post-Graduation Selection Using Multi-Criteria Decision Analysis.....	178
VP66 Perception Of Decision Makers And Researchers Towards Health Technology Assessment In Ghana.....	179
VP67 The Value Of The European Network For Health Technology Assessment (EUnetHTA) Outputs For National Health Technology Assessment: The French Experience.....	180
VP69 Mapping Brazilian Nuclear Medicine Installed Capacity And Perspectives.....	180
VP70 Structuring The Process Of Innovation Uptake In Tunisia.....	181
VP71 Health Technology Assessment In Japan: Current Issues And Challenges.....	182
VP72 Development Trend Analysis On New Health Technology: Based On Euroscan.....	183
VP74 Russian System Of Medicines Provision: Status And Future Aspects.....	183
VP76 European Collaboration In Health Technology Assessment – Experiences And Possible Benefits.....	184
VP78 Cross-Country Variation In Health Technology Assessment Preferences: An International Survey.....	185
VP81 Health Technology Assessment And Rare Disease Decision Making: Focus On Orphan Drugs.....	186
VP83 How To Identify Technologies Eligible For Health Technology Assessment: A Bottom-Up Approach.....	187
VP84 A Synthetic Index To Assess The Quality Of Care Of Acute Hospitals.....	188
VP87 Extrapolation From Progression Free Survival To Overall Survival In Oncology.....	188
VP88 Transient Ischaemic Attack Referral (TIER) Intervention Development.....	189
VP89 Assessing mHealth: Proposal Of A New Framework.....	190
VP90 Uniform Assessment Methods To Assess New Genomic Tests.....	190
VP94 Framework Of High-Quality Value Assessment Criteria In Health Care.....	191
VP95 The Monetary Value Of A Statistical Life Year: A Systematic Review.....	192
VP96 Information Flow As Base For Planning Biomedical Technologies In Italy.....	193
VP99 Economic Impact Of rpfVIII In The Management Of Acquired Hemophilia A.....	194
VP100 Disease Modelling Approaches In Multiple Sclerosis.....	194
VP101 Medical Devices For Treatment-resistant Hypertension: Health Technology Assessment Report.....	195
VP102 The Determinants Of Diffusion Of New Technologies Across Life Cycle.....	196
VP103 Health Technology Assessment Of Genetic Tests For Cystic Fibrosis Carrier Screening In Italy.....	197
VP107 Pharmaceutical Industry's Experiences with the German Health Technology Assessment Scientific Advice.....	197
VP108 Environmental Sustainability In Hospitals Health Technology Assessment - A Survey.....	198

VP109 Identifying Priorities For A National Health Research Funder	199
VP110 Building Capacity In Health Technology Assessment Through Plain Language	200
VP111 Referral Center For Multiple Myeloma Patient Care	201
VP113 Reframing “Disinvestment”: Appropriateness And Real-Time Data Capture	201
VP115 Practical Issues Of Using Real-World Data In Effectiveness Research	202
VP116 Comparison Between Time To Off Treatment And Italian Medicines Agency Registries Treatment Duration	203
VP120 A United Kingdom Research Commissioning Framework For Devices And Diagnostics	204
VP122 Cryoballoon Versus Radiofrequency Ablation For Atrial Fibrillation	204
VP124 The End Of A French Medical Dogma For Hepatitis B And C Diagnosis	205
VP126 The Effectiveness And Safety Of Barbed Sutures In Bariatric Surgery	206
VP129 Social Cost Benefit Analysis (SCBA) Of Three Alcohol Policy Measures	207
VP130 Burden Of Illness For Urothelial Bladder Cancer (UBC) In Italy	208
VP131 Comparison Of Variation Methods For One-Way Sensitivity Analyses	208
VP132 Cost Effectiveness Of A Predictive Risk Model In Primary Care	209
VP133 Patient-Reported Health State Utilities In Neuroendocrine Tumours	210
VP135 Clustering Surgical Indicators And Predictors Of Catastrophic Expenses	210
VP136 The Impact Of Hospital Costing Methods On Economic Evaluations	211
VP137 Why We Should Not Meet Unmet Needs!	212
VP138 Integration Of Ethics In Health Technology Assessment	212
VP140 Methods For Ethical Analysis In The Health Technology Assessment	213
VP142 Assessing Human Enhancements: Exposing And Elucidating Ethical Issues	214
VP144 Health Technology Assessment In Hospitals: Determinants Of Performance	215
VP146 A Comparative Assessment Of 3D/2D Laparoscopic Display Systems	216
VP147 Implementing Electronic Health Record In A Children’s Hospital	216
VP148 Health Technology Assessment Of Femtosecond Laser: A New Frontier In Cataract Surgery	217
VP149 Sustained Low Efficiency Dialysis (SLED): A Rapid Review	218
VP151 Endovenous Iron Deficiency Anemia Treatment In Inflammatory Bowel Disease: Hospital-based Health Technology Assessment	219
VP155 Synchronization Of Regulatory Approval And Health Technology Assessment Recommendation Timing	220
VP157 What Is The Response To Immuno-Oncology By Health Technology Assessment Agencies?	220
VP159 Strengthening Primary Health Care In Nigeria By Patient Involvement	221
VP161 Identification Of Needs Of Pigmented Villonodular Synovitis Patients Using Online Bulletin Board	222
VP163 Patient Involvement In The Development Of Multi-Criteria Decision Tool	223
VP164 Applying Health Technology Assessment To Pharmacy: The Italian-Medicine-Use-Review-Health Technology Assessment	223
VP165 Landscape Assessment: Patient Engagement In Health Technology Assessment	224
VP166 Selecting Rapid Review Methods For Health Technology Assessment	225
VP167 Comparison Of Methodology In Mixed Treatment Comparisons Of Treatments For Multiple Sclerosis	226
VP168 Assessment Of Plasmapheresis For Alzheimer’s Disease Systematic Review	227
VP169 Grouping Treat-to-Target Studies In Systematic Reviews	227
.....	

VP171 The Safety Of Barbed Sutures In Cosmetic Surgery.....	228
VP172 Clinical Effectiveness Of A Predictive Risk Model In Primary Care.....	229
VP173 Determinants Of Behavioral Health System Efficiency In Organisation For Economic Co-operation And Development (OECD) Countries.....	229
VP174 Atlases Of Quality: Assessing Integrated Care In Chronic Diseases.....	230
VP175 Validating Outcome Assessments For Health Technology Assessment In Ceroid Lipofuscinosis Neuronal 2 (CLN2), An Ultra-Rare Disease.....	231
VP176 Effectiveness Of Anti-Tumor Necrosis Factor In Patients With Psoriatic Arthritis.....	232
VP177 Older People With Cancer: To Treat Or Not To Treat With Chemotherapy?.....	232
VP180 Effect Of Two-Invoice System On Drug Distribution And Price In China.....	233
VP181 From National To European Assessment - The German Case.....	234
VP182 Network Amongst The Health Technology Assessment Ecosystem.....	235
VP184 A Cost Analysis Of Flash Glucose Monitoring Systems In Veneto Region.....	235
VP189 Hemolysis Induced By Modern Infusion Pumps During Blood Transfusion.....	236
VP190 A Review Of Best Practices In Five Mental Disorders In Youth.....	237
VP191 Peripheral Nerve Field Stimulation For Chronic Low Back Pain.....	238
VP192 Importance Of Contextual Data In Producing Health Technology Assessment Recommendations.....	238
VP194 Health Technology Assessment Applied To Nurse Retention And Development: A Sickle Cell Example.....	239
VP195 Using The ISSG Search Filter Resource In Health Technology Assessment.....	240
VP196 Impact Of Trial Registry Search Features On Searches In CT.gov/ICTRP.....	240
VP197 Sustainable Production Of Rapid Health Technology Assessments And Clinical Guidelines.....	241
VP198 Efficient Retrieval Of Trial Protocols: An Empirical Study.....	242
VP199 Limitations Of Studies On Oxygen Therapy In Acute Care Settings.....	242
VP200 Untangling What Information Specialists Should Document and Report.....	243
VP201 From A Systematic Review To Addressing Evidence Gaps.....	244
VP203 Performance Evaluation Of Eye-Tracking Devices.....	245
VP205 Implementing Electronic Records In Ambulances.....	246
VP208 Informing An Economic Model For Hyperhidrosis: A Clinical Survey.....	246
VP209 Two-Way Short Message Service (SMS) For Better Engagement And Quality Bio-Surveillance System.....	247
VP214 Criteria That Influence The Brazilian Public Decision-Making.....	248
VP216 Health Technology Assessment's Balance Between Additional Data, Adoption, And Patient Access.....	248

Erratum.....250

International Journal Of Technology Assessment In Health Care 2017 Supplement—Erratum.....	250
--	-----